

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/541,216	
			Filing Date	06/29/2005	
			First Named Inventor	Mark Tawa	
			Art Unit	1617	
			Examiner Name	D. Claytor	
Sheet	1	of	35	Attorney Docket Number	TPI5013USPCT6

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-2,711,411	06-21-1955	Holbert, <i>et al.</i>	All
		US-3,028,420	04-03-1962	Petrow <i>et al.</i>	All
		US-3,536,809	04-09-1991	Schaller <i>et al.</i>	All
		US-3,598,123	08-10-1971	Zaffaroni	All
		US-3,845,770	11-05-1974	Theeuwes <i>et al.</i>	All
		US-3,916,899	11-04-1975	Theeuwes <i>et al.</i>	All
		US-4,008,719	02-22-1977	Theeuwes <i>et al.</i>	All
		US-4,198,507	04-15-1980	Barry, <i>et al.</i>	All
		US-4,267,179	05-12-1981	Heeres <i>et al.</i>	All
		US-4,368,197	01-11-1983	Shefter, <i>et al.</i>	All
		US-4,513,006	04-23-1995	Maryanoff <i>et al.</i>	All
		US-4,764,604	08-16-1988	Muller	All
		US-4,916,134	04-10-1990	Heeres <i>et al.</i>	All
		US-4,994,604	02-19-1991	Tung, <i>et al.</i>	All
		US-5,006,513	04-09-1991	Hector <i>et al.</i>	All
		US-5,059,595	10-22-1991	Le Grazie	All
		US-5,073,543	12-17-1991	Marshall <i>et al.</i>	All
		US-5,120,548	06-09-1992	McClelland <i>et al.</i>	All

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/541,216	
			Filing Date	06/29/2005	
			First Named Inventor	Mark Tawa	
			Art Unit	1617	
			Examiner Name	D. Claytor	
Sheet	2	of	35	Attorney Docket Number	TPI5013USPCT6

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,177,262	01-15-1993	Taylor, <i>et al.</i>	All
		US-5,242,942	09-07-1993	Costanzo <i>et al.</i>	All
		US-5,332,834	07-26-1994	Bhattacharya, <i>et al.</i>	All
		US-5,338,644	08-16-1994	Taylor, <i>et al.</i>	All
		US-5,354,556	10-11-1994	Sparks <i>et al.</i>	All
		US-5,366,738	11-22-1994	Rork <i>et al.</i>	All
		US-5,380,867	01-10-1995	Bhattacharya, <i>et al.</i>	All
		US-5,384,327	01-24-1995	Costanzo <i>et al.</i>	All
		US-5,412,094	05-02-1995	Amos, <i>et al.</i>	All
		US-5,414,997	05-16-1995	Tailer	All
		US-5,474,997	12-12-1995	Gray <i>et al.</i>	All
		US-5,523,090	06-04-1996	Znaiden, <i>et al.</i>	All
		US-5,591,767	01-07-1997	Mohr <i>et al.</i>	All
		US-5,614,342	03-25-1997	Molaire, <i>et al.</i>	All
		US-5,633,015	05-27-1997	Gilis <i>et al.</i>	All
		US-5,639,476	06-17-1997	Oshlack <i>et al.</i>	All
		US-5,661,151	08-26-1997	Saksena <i>et al.</i>	All
		US-5,674,533	10-07-1997	Santus <i>et al.</i>	All
		US-5,707,975	01-13-1998	Francois <i>et al.</i>	All
		US-5,733,566	03-31-1998	Lewis	All

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/541,216	
			Filing Date	06/29/2005	
			First Named Inventor	Mark Tawa	
			Art Unit	1617	
			Examiner Name	D. Claytor	
Sheet	3	of	35	Attorney Docket Number	TPI5013USPCT6

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,753,693	05-19-1998	Shank	All
		US-5,760,007	06-02-1999	Shank <i>et al.</i>	All
		US-5,935,933	08-10-1999	Shank <i>et al.</i>	All
		US-5,952,187	09-14-1999	Stenglein <i>et al.</i>	All
		US-5,998,380	12-07-1999	Ehrenberg <i>et al.</i>	All
		US-5,998,413	12-07-1999	Heeres, <i>et al.</i>	All
		US-6,001,996	12-14-1999	Amos, <i>et al.</i>	All
		US-6,071,537	06-06-2000	Shank	All
		US-6,132,420	10-17-2000	Dionne <i>et al.</i>	All
		US-6,191,117	02-20-2001	Kozachuk	All
		US-6,201,010	03-13-2001	Cottrell	All
		US-6,245,357	06-12-2001	Edgren <i>et al.</i>	All
		US-6,268,385	07-31-2001	Whittle, <i>et al.</i>	All
		US-6,270,787	08-07-2001	Ayer	All
		US-6,283,953	09-04-2001	Ayer <i>et al.</i>	All
		US-6,287,295	09-11-2001	Chen <i>et al.</i>	All
		US-6,319,903	11-20-2001	Carrazana <i>et al.</i>	All
		US-6,333,050	12-25-2001	Wong <i>et al.</i>	All
		US-6,365,185	04-02-2002	Ritschel <i>et al.</i>	All
		US-6,375,978	04-23-2002	Kleiner <i>et al.</i>	All

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Art Unit	1617
				Examiner Name	D. Claytor
Sheet	4	of	35	Attorney Docket Number	TPI5013USPCT6

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-6,488,962	12-03-2002	Berner et al.	All
		US-6,503,884	01-07-2003	Ehrenberg et al.	All
		US-6,559,293	05-06-2003	Almarsson, et al.	All
		US-6,570,036	05-27-2003	Reuter	All
		US-6,699,840	03-02-2004	Almarsson, et al.	All
		US-7,078,526	07-18-2006	Remenar et al.	All
		US-7,205,413	04-17-2007	Morissette et al.	All
		US-7,446,107	11-04-2008	Remenar et al.	All
		US-7,452,555	11-18-2008	Childs	All
		US-2002/0037925	03-28-2002	Dewey et al.	All
		US-2002/0042446	04-11-2002	Dewey et al.	All
		US-2003/0069190	04-10-2003	Abdel-Magid et al.	All
		US-2003/0072802	04-17-2003	Cutler	All
		US-2003/0096014	05-22-2003	Sherman	All
		US-2003/0162226	08-28-2003	Cima, et al.	All
		US-2003/0166581	09-04-2003	Almarsson, et al.	All
		US-2003/0224006	12-04-2003	Zaworotko, et al.	All
		US-2004/0019211	01-29-2004	Remenar, et al.	All

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Art Unit	1617
				Examiner Name	D. Claytor
Sheet	5	of	35	Attorney Docket Number	TPI5013USPCT6

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-2004/0106052	06-03-2004	Molaire	All
		US-2004/0106053	06-03-2004	Molaire, et al.	All
		US-2004/0106055	06-03-2004	Molaire, et al.	All
		US-2004/0171062	09-02-2004	Hirth, et al.	All
		US-2004/0176335	09-09-2004	Childs	All
		US-2004-0053853	03-18-2004	Almarsson, et al.	All
		US-2005/0070551	03-31-1995	Remenar, et al.	All
		US-2005/0070551 A1	03-31-2005	Remenar, et al.	All
		US-2005/0169982	08-04-2005	Almarsson, et al.	All
		US-2005/0181041	08-18-2005	Goldman	All
		US-2005/0252649	11-17-2005	Chiu, et al.	All
		US-2005/0256127	11-17-2005	Ku, et al.	All
		US-2007/0293674	120-20-2007	Scoppettuolo et al.	All

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
		EP 413528 B1		11-15-1995	Yu, R. <i>et al.</i>	All	
		EP 1364649 A1		11-26-2003	Cilag AG	All	
		WO 94/16733 A1		08-04-1994	Chiesi Farmaceutici S.P.A.	All	
		WO 96/07331 A1		03-14-1996	Xyrofin Oy	All	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Art Unit	1617
				Examiner Name	D. Claytor
Sheet	6	of	35	Attorney Docket Number	TPI5013USPCT6

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 98/57967 A1	12-23-1998	Dong-A Pharmaceutical Co., Ltd.	All	
		WO 2000/53283 A1	09-14-2000	Reuter Chemische Apparatebau KG	All	
		WO 2001/13904 A2	03-01-2001	Ortho-McNeil Pharmaceutical, Inc.	All	
		JP 54-16494	02-07-1979	Yamanouchi Pharmaceutical Co., Ltd.	All	X
		WO 00/50020 A2	08-31-2000	University of Cincinnati	All	
		FR 769,586	06-11-1934	Chemische Fabrik von Heyden	All	X
		IT 01303251	11-06-2000	Industriale Chimica, S.R.L.	All	X
		WO 2001/97853 A1	12-27-2001	Biochemie Gesellschaft MBH	All	
		EP 0310122 B1	04-05-1989	Kaken Pharma	All	
		WO 2002/062318 A2	08-15-2002	DSM N.V.	All	
		EP 0283992 B1	09-16-1992	Janssen Pharma	All	
		WO 2003/101392 A2	12-11-2003	Transform Pharmaceuticals, Inc.	All	
		WO 2004/054571 A1	07-01-2004	Cilag AG	All	
		WO 2004/078161 A1	09-16-2004	Transform Pharmaceuticals, Inc.	All (provided in 3 parts due to file size)	
		WO 2004/089313 A2	10-21-2004	Transform Pharmaceuticals, Inc.	All	
		WO 2005/023198 A2	03-17-2005	Transform Pharmaceuticals, Inc.	All	
		WO 2005/037424 A1	04-28-2005	Salvias AG	All	
		WO 2005/055983 A2	06-23-2005	Medcrystalforms, LCC	All	
		WO 2005/060968 A1	07-07-2005	Sepracor, Inc.	All	
		WO 2005/089375 A2	09-29-2005	S.S.C.I., Inc.	All	
		WO 2005/094804 A1	10-13-2005	The Regents of the University of Michigan	All	
		WO 2006/024930 A1	03-09-2006	Pharmacia and Upjohn Co., LCC	All	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	7	of	35	Attorney Docket Number	TPI5013USPCT6

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 03/070738 A2	08-28-2003	Transform Pharmaceuticals, Inc.	All	
		WO 03/074474 A2	09-12-2003	Univ. South Fl	All	
		WO 95/17407 A1	06-29-1995	Schering Corp	All	
		WO 00/07583 A2	02-17-2000	Brookhaven Science Associates	All	
		WO 00/72841 A1	12-07-2000	Berlant, Jeffrey	All	
		WO 03 033462 A2	04-23-2003	Regents of Univ. Mich.	All	
		IN 182620	12-24-1994	Bajaj <i>et al.</i>	All	
		GB 1 297 261 A	11-22-1972 (22 Nov 1972)	E.R. Squibb & Sons, Inc.	whole document	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AAKERÖY, C. <i>et al.</i> "Crystal engineering of hydrogen-bonded assemblies- a progress report" <i>Aust. J. Chem.</i> , 2001, pp. 409-421, Vol. 54.	
		BINGHAM, A. <i>et al.</i> "Over one hundred solvates of sulfathiazole" <i>Chem. Commun.</i> , 2001, pp. 603-604.	
		BYRIEL, K., <i>et al.</i> "Molecular cocrystals of carboxylic acids. IX Carboxylic acid interactions with organic heterocyclic bases. The crystal structures of the adducts of (2,4-dichlorophenoxy) acetic acid with 3-hydroxypyridine, 2,4,6,-trinitrobenzoic acid with 2-aminopyrimidine, and 4-nitrobenzoic acid with 3-amino-1,2,4-triazole" <i>Aust. J. Chem.</i> , 1992, pp. 969-981, Vol. 45, No. 6.	
		SALMON, J. <i>et al.</i> "Supramolecular chemistry of boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
		URBINA, J. <i>et al.</i> "Supramolecular design of inorganic/organic networks using flexible ligands with self-complementary hydrogen bonds (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/541,216	
				Filing Date	06/29/2005	
				First Named Inventor	Mark Tawa	
				Group Art Unit	1617	
Examiner Name	D. Claytor					
Attorney Docket Number	TPI5013USPCT6					
Sheet	8	of	35			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		SMITH, D. <i>et al.</i> "Structure confirmation by single crystal X-ray diffraction of a series of new schiff bases and theoretical computations on 3-(N-2- α , α , α -trifluorotoluylidene amino) tetrahydrothiophene-1, 1-dioxide (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.		
		DESIRAJU, G. "Supramolecular synthons in crystal engineering- A new organic synthesis" <i>Angew. Chem. Int. Ed. Engl.</i> , 1995, pp. 2311-2327, Vol. 34.		
		FRITCHIE, C. <i>et al.</i> "The configuration of phenothiazine in various molecular complexes" <i>Chem. Commun.</i> , 1968, pp. 833-834.		
		BALL, P. "Materials Chemistry - Scandal of Crystal Design ...", <i>Nature</i> , June 20, 1996, pp. 648-650, Vol. 381.		
		BERNSTEIN, J. <i>et al.</i> "Concomitant Polymorphs", <i>Angew. Chem., Int. Ed.</i> , 1999, pp. 3440-3461, Vol. 38.		
		ZAWOROTKO, M. J. "Crystal Engineering of Diamondoid Networks", <i>Chem. Soc. Rev.</i> , 1994, pp. 283-288, Vol. 23.		
		SHATTOCK, T. R. <i>et al.</i> "Hierarchy of Supramolecular Synthons: Persistent Carboxylic Acid ... Pyridine Hydrogen Bonds in Cocrystals that also contain a Hydroxyl Moiety" <i>Crystal Growth 7 Design</i> , 2008, pp. 4533-4545, Vol. 8, No. 12.		
		HUANG, C.-M. <i>et al.</i> "Molecular packing modes. Part XI. Crystal structures of the 2:1 complexes of benzamide with succinic acid and furamide with oxalic acid" <i>J. Chem. Soc. Perkins Trans. 2: Physical Organic Chemistry</i> , 1973, pp. 503-508, Vol. 5.		
		JACKISCH, M. <i>et al.</i> "Structures of three related biphenyl compounds: 4,4'-biphenyldiol, 3, 3',5,5'-tetra- <i>tert</i> -butyl-4,4'-biphenyldiol, and 3,3',5,5'- tetra- <i>tert</i> -butyl-1,1'-bicyclohexa-2,5-dienylidene-4,4'-dione" <i>Acta Cryst.</i> , 1990, pp. 919-922, Vol. C46.		
		KIM, S. <i>et al.</i> "The structure of a crystalline complex containing one phenobarbital molecule and two adenine derivatives" <i>Proc. Natl. Acad. Sci. USA</i> , 1968, pp. 402-408, Vol. 60.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	9	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		KOBAYASHI, H. <i>et al.</i> "Sinusoidal structure of the 1:1 complex of phenothiazine and 7,7,8,8-tetracyanoquinodimethane, PTZ-TCNQ" <i>Acta Cryst.</i> , 1974, pp. 1010-1017, Vol. B30.		
		ERMER, O. <i>et al.</i> "Molecular recognition among alcohols and amines: super-tetrahedral crystal architectures of linear diphenol-diamine complexes and aminophenols" <i>J. Chem. Soc. Perkins Trans. 2</i> , 1994, pp. 925-944.		
		MARTIN, R. <i>et al.</i> "Polyphenal-caffeine complexation" <i>J. Chem. Soc., Chem. Commun.</i> , 1986, pp. 105-106.		
		LEHN, J.-M. <i>et al.</i> "Molecular recognition directed self-assembly of ordered supramolecular strands by cocrystallization of complementary molecular components" <i>Chem. Soc., Chem. Commun.</i> , 1990, pp. 479-481.		
		BOUCHER, E. <i>et al.</i> "Use of Hydrogen-Bonds to Control Molecular Aggregation. Behavior of Dipyrindones and Pyridone-Pyrimidones Designed to Form Cyclic Triplexes", <i>J. Org. Chem.</i> , 1995, pp. 1408-1412, Vol. 60.		
		CHANG, Y. L. <i>et al.</i> "An Approach to the Design of Molecular-Solids. Strategies for Controlling the Assembly of Molecules Into Two-Dimensional Layered Structures", <i>J. Am. Chem. Soc.</i> , 1993, pp. 5991-6000, Vol. 115.		
		DESIRAJU, G. R. "Crystal Gazing: Structure Prediction and Polymorphism", <i>Science</i> , October 17, 1997, pp. 404-405, Vol. 278, No 5337.		
		FEYNMAN, R. "There's Plenty of Room at the Bottom", <i>Engineering and Science</i> , February 1960, pp. 22-36.		
		MOULTON, B. <i>et al.</i> "From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids", <i>Chem. Rev.</i> , 2001, pp. 1629-1658, Vol. 101.		
		LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XV* Preparation and characterization of heterocyclic base adducts with a series of carboxylic acids, and the crystal structures of the adducts of 2-aminopyrimidine with 2,6-dihydroxybenzoic acid, 4-aminobenzoic acid, phenoxyacetic acid, (2,4-dichlorophenoxy) acetic acid, (3,4-dichlorophenoxy)-acetic acid and salicylic acid, and 2-aminopyrimidine with 2,6-dihydroxybenzoic acid" <i>Aust. J. Chem.</i> , 1994, pp. 1097-1115, Vol. 47.		
		MCINTOSH, J. <i>et al.</i> "Chemotherapeutic drugs in anaerobic infections of wounds" <i>The Lancet</i> , June 26, 1943, pp. 793-795.		
		MCINTOSH, J. <i>et al.</i> "Zinc peroxide, proflavine and penicillin in experimental cl. welchii infections" <i>The Lancet</i> , December 26, 1942, pp. 750-752.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	10	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SMITH, G. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXI The role of secondary group interactions in adduct formation between 2-aminopyrimidine and substituted benzoic acids: the crystal structures of the adducts with <i>o</i> -phthalic acid, <i>o</i> -nitrobenzoic acid, <i>o</i> -aminobenzoic acid and <i>m</i> -aminobenzoic acid" <i>Aust. J. Chem.</i> , 1995, pp. 1151-1166, Vol. 48.	
		WEISSBUCH, I. <i>et al.</i> "Crystal morphology control with tailor-made additives; a stereochemical approach" <i>Advances in Crystal Growth Research</i> , 2001, pp. 381-400.	
		MCMAHON, J. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. 3 ¹ . Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals" <i>Z. Kristallogr.</i> , 2005, pp. 340-350, Vol. 220.	
		MEEJOO, S. <i>et al.</i> "The interplay of aryl-perfluoroaryl stacking interactions and interstack hydrogen bonding in controlling the structure of a molecular cocrystal" <i>Chemphyschem</i> , 2003, pp. 766-769, Vol. 4.	
		MIRMEHRABI, M. <i>et al.</i> "Improving the filterability and solid density of ranitidine hydrochloride form 1" <i>Journal of Pharmaceutical Sciences</i> , July 2004, pp. 1692-1700, Vol. 93, No. 7.	
		MORRIS, K. <i>et al.</i> "Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 91-114, Vol. 48.	
		NAKANISHI, I. <i>et al.</i> "X-ray structural studies on two forms of β -cyclodextrin barbitol complexes" <i>Journal of Inclusion Phenomena</i> , 1984, pp. 689-699, Vol. 2.	
		NAKAO, S. <i>et al.</i> "The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital" <i>Acta Cryst.</i> , 1977, pp. 1373-1378, Vol. B33.	
		NATARAJAN, S. <i>et al.</i> "Reinvestigation of the crystal structure of diglycine hydrochloride" <i>Zeitschrift für Kristallographic</i> , 1992, pp. 265-270, Vol. 198.	
		OLENIK, B. <i>et al.</i> "Cooperative and anticooperative effects in the cocrystals of mono- and diazanaphthalenes with meso-1, 2-diphenyl-1,2-ethanediol" <i>Crystal Growth & Design</i> , 2003, pp. 175-181, Vol. 3, No. 2.	
		OLENIK, B. <i>et al.</i> "Supramolecular synthesis by cocrystallization of oxalic and fumaric acid with diazanaphthalenes" <i>Crystal Growth & Design</i> , 2003, pp. 183-188, Vol. 3, No. 2.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	11	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GROTH, P. " <i>d</i> -Glucose-sodium chloride-monohydrate (glucose-sodium chloride) = 2C ₆ H ₁₂ O ₆ .NaCl.H ₂ O" <i>Chemische Krystallographie</i> , 1910, pp. 438-439.	X
		OSWALD, I. <i>et al.</i> "Rationalisation of co-crystal formation through knowledge-mining" <i>Crystallography Reviews</i> , 2004, pp. 57-66, Vol. 10, No. 1.	
		OUYANG, X. <i>et al.</i> "Single-crystal-to-single-crystal topochemical polymerizations of a terminal diacetylene: two remarkable transformations give the same conjugated polymer" <i>J. Am. Chem. Soc.</i> , 2003, pp. 12400-12401, Vol. 125.	
		PATEL, U. <i>et al.</i> "Structure of the 1:1 complex between 4-amino- <i>N</i> -(4,6-dimethyl-2-pyrimidinyl)- benzenesulfonamide (sulfadimidine) and 2-hydroxybenzoic acid (salicylic acid)" <i>Acta Cryst.</i> , 1988, pp. 1264-1267, Vol. C44.	
		REDDY, L. <i>et al.</i> "Phenyl-perfluorophenyl synthon mediated cocrystallization of carboxylic acids and amides" <i>Crystal Growth & Design</i> , 2004, pp. 89-94, Vol. 4., No. 1.	
		REMENAR, J. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.	
		SCHMIDT, G. "Photodimerization in the solid state" <i>Pure Appl. Chem.</i> , 1971, pp. 647-678, Vol. 27.	
		SHAN, N. <i>et al.</i> "Co-crystal of 4,7-phenanthroline and carboxylic acids: synthon competition and prediction" <i>Tetrahedron Letters</i> , 2002, pp. 8721-8725, Vol. 43.	
		SHAN, N. <i>et al.</i> "Crystal engineering using 4,4'-bipyridyl with di- and tricarboxylic acids" <i>Crystal Engineering</i> , 2002, pp. 9-24, Vol. 5.	
		SHAN, N. <i>et al.</i> "Supramolecular synthons in the co-crystal structures of 2-aminopyrimidine with diols and carboxylic acids" <i>Tetrahedron Letters</i> , 2002, pp. 3101-3104, Vol. 43.	
		MCINTOSH, J. <i>et al.</i> "Further observations on the chemotherapy of experimental gas gangrene: flavazole, marfanil, V187 and V335" <i>British Journal of Experimental Pathology</i> , 1946, pp. 46-54, Vol. 27.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	12	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SHAVIV, R. <i>et al.</i> "Magnetochemistry of the tetrahaloferrate (III) ions 6. Crystal structure and magnetic ordering in [(pyH) ₃ Cl] [FeCl ₄] ₂ " <i>Inorganica Chimica Acta</i> , 1992, pp. 613-621, Vol. 198-200.	
		SHEFTER, E. "Structural studies on complexes IV: Crystal structure of a 1:1 5-chlorosalicylic acid and theophylline complex" <i>Journal of Pharmaceutical Sciences</i> , 1969, pp. 710-714, Vol. 58.	
		SHIMIZU, N. <i>et al.</i> "Structure of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine-5,5-diethylbarbituric acid (1:1)" <i>Acta Cryst.</i> , 1982, pp. 2309- 2311, Vol. B38.	
		SINGH, N. B. <i>et al.</i> "Solid state reaction between 8-hydroxyquinoline and <i>p</i> -nitrobenzoic acid" <i>Indian Journal of Chemistry</i> , May 1988, pp. 429-432, Vol. 37B.	
		SMITH, G. <i>et al.</i> "The 1:1 adduct of 4-aminobenzoic acid with 4-aminobenzonitrile" <i>Acta Cryst.</i> , 2000, pp. 1155-1156, Vol. C56.	
		STEINER, T. "Donor and acceptor strengths in C-H...O hydrogen bonds quantified from crystallographic data of small solvent molecules" <i>New. J. Chem.</i> , 1998, pp. 1099-1103.	
		STOREY, R. <i>et al.</i> "Automation of solid form screening procedures in the pharmaceutical industry- how to avoid the bottlenecks" <i>Crystallography Reviews</i> , 2004, pp. 45-56, Vol. 10, No. 1.	
		SZAFRAN, M. <i>et al.</i> "Molecular structures and hydrogen bonding in the 1:1 and 1:2 complexes of pyridine betaine with 2,6-dichloro-4-nitrophenol; an example of strongly coupled hydrogen bonds, O-H...O=C-O-H...O-" <i>Journal of Molecular Structure</i> , 1997, pp. 145-160, Vol. 416.	
		TAKEUCHI, M. <i>et al.</i> "Synchrotron radiation SAXS/WAXS study of polymorph-dependent phase behavior of binary mixtures of saturated monoacid triacylglycerols" <i>Crystal Growth & Design</i> , 2003, pp. 369-374, Vol. 3, No. 3.	
		TANG, C. P. <i>et al.</i> "Reaction pathways in crystalline host-guest inclusion complexes: rotation by a net 180° of the acetyl group on photoaddition of guest- acetophenone and - <i>m</i> - Chloroacetophenone to the atom C5 of host deoxycholic acid" <i>J. Am. Chem. Soc.</i> , 1985, pp. 4058-4070, Vol. 107.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	13	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		TAYLOR, R. et al. "Rules governing the crystal packing of mono- and dialcohols" <i>Acta Crystallographica Section B, Structural Science</i> , 2001, pp. 815-827, Vol. B57.		
		THALLAPALLY, P. et al. "Polymorphism of 1,3,5-trinitrobenzene induced by a trisindane additive" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 1149-1155, Vol. 43.		
		TIMMERMAN, P. et al. "Noncovalent Assembly of functional groups on calix[4]arene molecular boxes" <i>Chem. Eur. J.</i> , 1997, pp. 1823-1832, Vol. 3., No. 11.		
		SHAN, N. et al. "Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics" <i>Chem. Commun.</i> , 2002, pp. 2372-2373.		
		CAIRA, M. et al. "X-ray structure and thermal analysis of a 1:1 complex between (S)-naproxen and heptakis (2,3,6-tri-O-methyl)- β -cyclodextrin" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1995, pp. 277-290, Vol. 20, pp. 11-15.		
		TRASK, A. et al. "Crystal engineering of organic cocrystals by the solid-state grinding approach" <i>Top Curr. Chem.</i> , 2005, pp. 41-70, Vol. 254.		
		TRASK, A. et al. "Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration" <i>Crystal Growth & Design</i> , 2005, pp. 1013-1021, Vol. 5, No. 3.		
		TRASK, A. et al. "Solvent-drop grinding: green polymorph control of cocrystallisation" <i>Chem. Commun.</i> , 2004, pp. 890-891 in addition to supplemental materials.		
		TROWBRIDGE, L. et al. "Composites for nonlinear optics: Crystal growth and polymorphism" <i>University of Sussex, Falmer Brighton UK, School of Chemistry and Molecular Sciences</i> , pp. 272.		
		UNO, T. et al. "Structure of 5,5-diphenylhydantoin-1- (4-bromophenyl)-4-dimethylamino-2,3-dimethyl-3-pyrazolin-5-one (1:1)" <i>Acta Cryst.</i> , 1980, pp. 2794-2796, Vol. B36.		
		VAN ROEY, P. et al. "Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B" <i>J. Enzyme Inhibition</i> , 1991, pp. 119-132, Vol. 5.		
		VAN ROEY, P. et al. "Structure of <i>cis</i> -1-[[4-(1-imidazolylmethyl) cyclohexyl] methyl] imidazole- succinic acid complex" <i>Acta Cryst.</i> , 1991, pp. 1015-1018, Vol. C47.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	14	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		VISHWESHWAR, P. <i>et al.</i> "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients" <i>Chem. Commun.</i> , 2005, pp. 4601-4603.		
		VISHWESHWAR, P. <i>et al.</i> "Recurrence of carboxylic acid- pyridine supramolecular synthon in the crystal structures of some pyrazinecarboxylic acids" <i>J. Org. Chem.</i> , 2002, pp. 556-565, Vol. 67.		
		VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid" <i>Chem. Commun.</i> , 2002, pp. 1830-1831.		
		VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons in phenol-isonicotinamide adducts" <i>Cryst. Eng. Comm.</i> 2003, pp. 164-168, Vol. 5, No. 31.		
		VOET, D. <i>et al.</i> "The crystal and molecular structure of the intermolecular complex 9-ethyladenine-5, 5-diethylbarbituric acid" <i>Journal of the American Chemical Society</i> , November 15, 1972, pp. 8213-8222, Vol. 94, No. 23.		
		VOET, D. <i>et al.</i> "The structure of an intermolecular complex between cytosine and 5-fluorouracil" <i>Journal of the American Chemical Society</i> , May 21, 1969, pp. 3069-3075, Vol. 91, No. 11.		
		STEZOWSKI, J. J. <i>et al.</i> "Characterization of a 1:1 complex of an unusual structure in the phenothiazine/phenazine binary phase diagram" <i>Zeitschrift fur Kristallographie in International Journal for Structural, Physical, Chemical Aspects of Crystalline Materials</i> , 1983, pp. 213-215, Vol. 162, No. 1-4.	X	
		WANG, A. <i>et al.</i> "Crystal structure of 1:1 complex of barbitol with 1-methylimidazole" <i>Journal of Pharmaceutical Sciences</i> , March 1979, pp. 361-363, Vol. 68, No. 3.		
		ALBEROLA, S. <i>et al.</i> "Crystalline and Molecular Structure of Sulfanilimide-Antipyrine" <i>Acta Cryst.</i> , 1977, pp. 3337-3341, Vol. B33.	X	
		WOOD, R. A. <i>et al.</i> "2,5-O-methylene-D-mannitol sodium-chloride, C ₇ H ₁₄ O ₆ . NaCl" <i>Cryst. Struct. Comm.</i> , 1976, 207-210, Vol. 5.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	15	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		XU, J. <i>et al.</i> "Effect of composition distribution on miscibility and co-crystallization phenomena in the blends of low density polyethylene with conventional and metallocene-based ethylene-butene copolymers" <i>Polymer</i> , 2001, pp. 3867-3874, Vol. 42.		
		YOO, J. <i>et al.</i> "Cocrystallization of a dinuclear platinum complex as a monomer and a one-dimensional polymer" <i>Polyhedron</i> , 2002, pp. 715-719, Vol. 21.		
		ZAITU, S. <i>et al.</i> "A 2:1 molecular complex of theophylline and 5-fluorouracil as the monohydrate" <i>Acta Cryst.</i> , 1995, pp. 1857-1859, Vol. C51.		
		ZAMAN, M. B. <i>et al.</i> "Linear hydrogen-bonded molecular tapes in the cocrystals of squaric acid with 4,4'-dipyridylacetylene and 1,2-bis(4-pyridyl) ethylene" <i>Acta Cryst.</i> , 2001, pp. 621-624, Vol. C57.		
		ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: hydrogen-bonded molecular "tapes" ¹ " <i>J. Am. Chem. Soc.</i> , 1990, pp. 9025-9026, Vol. 112.		
		ZERKOWSKI, J. <i>et al.</i> "Investigations into the robustness of secondary and tertiary architecture of hydrogen-bonded crystalline tapes" <i>Chem. Mater.</i> , 1994, pp. 1250-1257, Vol. 6.		
		ZERKOWSKI, J. <i>et al.</i> "New varieties of crystalline architecture produced by small changes in molecular structure in tape complexes of melamines and barbiturates" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4305-4315, Vol. 116.		
		ZERKOWSKI, J. <i>et al.</i> "Polymorphic packing arrangements in a class of engineered organic crystals" <i>Chem. Mater.</i> , 1997, pp. 1933-1941, Vol. 9.		
		ZERKOWSKI, J. <i>et al.</i> "Solid-state structures of "Rosette" and "Crinkled Tape" motifs derived from the cyanuric acid-melamine lattice" <i>J. Am. Chem. Soc.</i> , 1992, pp. 5473-5475, Vol. 114.		
		ZHANG, R. <i>et al.</i> "Atmospheric new particle formation enhanced by organic acids" <i>Science</i> , June 4, 2004, pp. 1487-1490 with additional supporting online material, Vol. 304.		
		ZHU, H. <i>et al.</i> "Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. theophylline" <i>International Journal of Pharmaceutics</i> , 1996, pp. 151-160, Vol. 135.		
		AAKERÖY, C. <i>et al.</i> "Aromatic dicarboxylic acids as building blocks of extended hydrogen-bonded architectures" <i>Supramolecular Chemistry</i> , 1998, pp. 127-135, Vol. 9.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	16	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		AAKERÖY, C. <i>et al.</i> "Assembly of 2-D inorganic/organic lamellar structures through a combination of copper (I) coordination polymers and self-complimentary hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 2000, pp. 3869-3872.		
		AAKERÖY, C. <i>et al.</i> "Building organic assemblies with 2-pyridone and dicarboxylic acids: relating molecular conformation and synthon stability to crystal structure" <i>Crystal Engineering</i> , 1998, pp. 225-241, Vol. 1, No. 3-4.		
		AAKERÖY, C. <i>et al.</i> "The C-H...C1 hydrogen bond: does it exist?" <i>New J. Chem.</i> , 1999, pp. 145-152.		
		AAKERÖY, C. <i>et al.</i> "Crystal engineering of ionic solids" <i>Modular Chemistry</i> (ed. by Michl, J.), 1997, pp. 153-162, Kluwer Academic Publishers, The Netherlands.		
		AAKERÖY, C. <i>et al.</i> "Crystal engineering: strategies and architectures" <i>Acta Cryst.</i> , 1997, pp. 569-586, Vol. B53.		
		AAKERÖY, C. <i>et al.</i> "Crystal engineering using intermolecular hydrogen-bonded connectors and classic coordination chemistry" <i>Transactions ACA</i> , 1998, pp. 97-103, Vol. 33.		
		AAKERÖY, C. <i>et al.</i> "The crystal structure of the molecular cocrystal L-malic acid L-tartaric acid (1/1)" <i>Supramolecular Chemistry</i> , 1996, pp. 153-156, Vol. 7.		
		AAKERÖY, C. <i>et al.</i> "Deliberate combination of coordination polymers and hydrogen bonds in a supramolecular design strategy for inorganic/organic hybrid networks" <i>Chem. Commun.</i> , 2000, pp. 935-936.		
		AAKERÖY, C. <i>et al.</i> "Di-hydroxy malonic acid as a building block of hydrogen-bonded 3-dimensional architectures" <i>Journal of Chemical Crystallography</i> , 1998, pp. 111-117, Vol. 28, No. 2.		
		AAKERÖY, C. <i>et al.</i> "Do polymorphic compounds make good cocrystallizing agents? A structural case study that demonstrates the importance of synthon flexibility" <i>Crystal Growth & Design</i> , 2003, 159-165, Vol. 3, No. 2.		
		AAKERÖY, C. <i>et al.</i> "Heteromeric intermolecular interactions as synthetic tools for the formation of binary co-crystals" <i>Cryst. Eng. Comm.</i> , 2004, pp. 19-24, Vol. 6, No. 5.		
		AAKERÖY, C. <i>et al.</i> "A high-yielding supramolecular reaction" <i>J. Am. Chem. Soc.</i> , 2002, 14425-14432, Vol. 124.		
		AAKERÖY, C. <i>et al.</i> "The hydrogen bond and crystal engineering" <i>Chemical Society Reviews</i> , 1993, pp. 397-407.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/541,216	
			Filing Date	06/29/2005	
			First Named Inventor	Mark Tawa	
			Group Art Unit	1617	
			Examiner Name	D. Claytor	
Sheet	17	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AAKERÖY, C. <i>et al.</i> "Hydrogen-bond assisted assembly of organic and organic-inorganic solids" <u>Crystal Engineering: From Molecules and Crystals to Materials</u> , 1999, pp. 89-106, Kluwer Academic Publishers, The Netherlands.	
		AAKERÖY, C. <i>et al.</i> "Hydrogen-bonding in solids" <u>Crystal Engineering</u> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 303-324, Kluwer Academic Publishers, The Netherlands.	
		AAKERÖY, C. <i>et al.</i> "Low-dimensional architectures of silver coordination compounds assembled <i>via</i> amide-amide hydrogen bonds" <u>Crystal Engineering</u> , 1998, pp. 39-49, Vol. 1, No. 1.	
		AAKERÖY, C. <i>et al.</i> "Molecular mechanics and crystal engineering" " <u>Crystal Engineering</u> (ed. by Seddon, K. R. <i>et al.</i>), 1999, pp. 69-82, Kluwer Academic Publishers, The Netherlands.	
		AAKERÖY, C. <i>et al.</i> "New building blocks for crystal engineering. Syntheses and crystal structures of oxime-substituted pyridines" <u>Cryst. Eng. Comm.</u> , 2000, pp. 1-6, Vol. 27.	
		AAKERÖY, C. <i>et al.</i> "Novel colorless composite materials for nonlinear optics" <u>Adv. Mater.</u> , 1993, pp. 364-367, Vol. 5, No. 5.	
		AAKERÖY, C. <i>et al.</i> "Organic assemblies of 2-pyridones with dicarboxylic acids" <u>Tetrahedron</u> , 2000, pp. 6693-6699, Vol. 56.	
		AAKERÖY, C. <i>et al.</i> "Pitfalls in the supramolecular assembly of silver(I) coordination compounds" <u>Journal of Molecular Structure</u> , 1999, pp. 91-101, Vol. 474.	
		AAKERÖY, C. <i>et al.</i> "A structural study of 2-amino-5-nitropyridine and 2-amino-3-nitropyridine: intermolecular forces and polymorphism" <u>J. Mater. Chem.</u> , 1998, pp. 1385-1389, Vol. 8, No. 6.	
		AAKERÖY, C. <i>et al.</i> "Supramolecular assembly of low-dimensional silver (I) architectures <i>via</i> amide-amide hydrogen bonds" <u>Chem. Commun.</u> , 1998, pp. 1067-1068.	
		AAKERÖY, C. <i>et al.</i> "'Total synthesis' supramolecular style: design and hydrogen-bond-directed assembly of ternary supermolecules" <u>Angew. Chem. Int. Ed.</u> , 2001, pp. 3240-3242, Vol. 40, No. 17.	
		AAKERÖY, C. <i>et al.</i> "Two-fold interpenetration of 3-D nets assembled <i>via</i> three-co-ordinate silver(I) ions and amide-amide hydrogen bonds" <u>J. Chem. Soc., Dalton Trans.</u> , 1998, pp. 1943-1945.	
		AHN, S. <i>et al.</i> "Polymorphs of a 1:1 cocrystal with tunnel and layer structures: <i>p,p'</i> -biphenol/dimethyl sulfoxide" <u>Crystal Growth & Design</u> , 2001, pp. 107-111, Vol. 1, No. 2.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/541,216	
			Filing Date	06/29/2005	
			First Named Inventor	Mark Tawa	
			Group Art Unit	1617	
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	18	of	35		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AKAZOME, M. <i>et al.</i> "Enantioselective inclusion of methyl phenyl sulfoxides and benzyl methyl sulfoxides by (R)-phenylglycyl-(R)-phenylglycine and the crystal structures of the inclusion cavities" <i>J. Org. Chem.</i> , 2000, pp. 68-76, Vol. 65.	
		AKHTARUZZAMAN, M.D. <i>et al.</i> "One-dimensional hydrogen-bonded molecular tapes in 1, 4-bis[(4-pyridinio) ethynyl]benzene chloranilate" <i>Acta. Cryst.</i> , 2001, pp. o353-o355, Vol. E57.	
		ALLEN, F. <i>et al.</i> "Systematic analysis of structural data as a research technique in organic chemistry" <i>Acc. Chem. Res.</i> , 1983, pp. 146-153, Vol. 16.	
		ALMARSSON, Ö. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?" <i>Chem. Commun.</i> , 2004, pp. 1889-1896.	
		AMAI, M. <i>et al.</i> "1:1 complex of octadecanoic acid and 3-pyridinecarboxamide" <i>Acta Cryst.</i> , 1998, pp. 1367-1369, Vol. C54.	
		ANDERSON, N. <i>et al.</i> "Sulfonation with inversion by mitsunobu reaction: an improvement on the original conditions" <i>J. Org. Chem.</i> , 1996, pp. 7955-7958, Vol. 61.	
		AOKI, K. <i>et al.</i> "A 1:1 complex of theophylline and p-nitrophenol" <i>Acta Cryst.</i> , 1978, pp. 2333-2336, Vol. B34.	
		ASHTON, P. <i>et al.</i> "Combining different hydrogen-bonding motifs to self-assemble interwoven superstructures" <i>Chem. Eur. J.</i> , 1998, pp. 577-589, Vol. 4, No. 4.	
		BARKER, P. A. <i>et al.</i> "Effect of crystallization temperature on the cocrystallization temperature on the cocrystallization of hydroxybutyrate/ hydroxyvalerate copolymers" <i>Polymer</i> , pp. 913-919, Vol. 38, No. 4.	
		BERKOVITCH-YELLIN, Z. <i>et al.</i> "Electron density distribution in cumulenes: an x-ray study of the complex allenedicarboxylic acid- acetamide (1:1) at -150° C" <i>Acta Cryst.</i> , 1977, pp. 3670-3677, Vol. B33.	
		BERKOVITCH-YELLIN, Z. <i>et al.</i> "The role played by C-H...O and C-H...N interactions in determining molecular packing and conformation" <i>Acta Cryst.</i> , 1984, pp. 159-165, Vol. B40.	
		BERL, V. <i>et al.</i> "Induced fit selection of a barbiturate receptor from a dynamic structural and conformational/configurational library" <i>Eur. J. Org. Chem.</i> , 1999, pp. 3089-3094.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	19	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		BERTOLASI, V. <i>et al.</i> "Competition between hydrogen bonding and donor-acceptor interactions in co-crystals of 1,3-dimethylbarbituric acid with aromatic amines" <i>New J. Chem.</i> , 2001, pp. 408-415, Vol. 25.		
		BERTOLASI, V. <i>et al.</i> "General rules for the packing of hydrogen-bonded crystals as derived from the analysis of squaric acid anions: aminoaromatic nitrogen base co-crystals" <i>Acta Cryst.</i> , 2001, pp. 591-598, Vol. B57.		
		BETTINETTI, G. <i>et al.</i> "Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim-sulfamethoxypyridazine 1:1 molecular complex" <i>Journal of Pharmaceutical Sciences</i> , April 2000, pp. 478-489, Vol. 89, No. 4.		
		BETTINETTI, G. <i>et al.</i> "Thermal analysis of binary systems of the pharmaceuticals trimethoprim and benzoic acid" <i>Journal of Thermal Analysis</i> , 1983, pp. 285-294, Vol. 28.		
		BETTIS, J. <i>et al.</i> "Biopharmaceutics and dosage form design" <i>Amer. J. Hosp. Pharm.</i> , March 1973, pp. 240-243, Vol. 30.		
		BOLTON, S. <i>et al.</i> "Complexes formed in solution by homologs of caffeine" <i>Journal of the American Pharmaceutical Association</i> , January 1957, pp. 38-41, Vol. XLVI, No. 1.		
		BOND, A. "In situ co-crystallisation as a tool for low-temperature crystal engineering" <i>Chem. Commun.</i> , 2003, pp. 250-251, Vol. 2.		
		BONIN, M. <i>et al.</i> "Urotropin azelate: a rather unwilling co-crystal" <i>Acta Cryst.</i> , 2003, pp. 72-86, Vol. B59.		
		BOSSHARD, C. <i>et al.</i> "Microscopic nonlinearities of two-component organic crystals" <i>J. Opt. Soc. Am. B</i> , November 2001, pp. 1620-1626, Vol. 18, No. 11.		
		GLUZMAN, M. Kh. <i>et al.</i> "Investigation of Eutectic Melting in Systems Composed of Organic Salts and Acids" <i>Journal of Physical Chemistry</i> , 1960, pp. 2742-2747, Vol. 34.		x
		BRAGA, D. <i>et al.</i> "Hydrogen bonding interactions between ions: a powerful tool in molecular crystal engineering" <i>Structure and Bonding</i> , 2004, pp. 1-32, Vol. 111.		
		BRIERLEY, C. <i>et al.</i> "Preparation and structure of the 1:2 π -molecular complex of phenothiazine with pyromellitic dianhydride" <i>J. Chem. Phys.</i> , February 1, 1985, pp. 1522-1528, Vol. 82, No. 1.		
Examiner Signature			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	20	of	35		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BURGI, H. <i>et al.</i> "Crystallisation of supramolecular materials" <i>Current Opinion in Solid State & Materials Science</i> , 1998, pp. 425-430, Vol. 3.	
		BYRN, S. R. <i>et al.</i> "Solid-state pharmaceutical chemistry" <i>Chem. Mater.</i> , 1994, pp. 1148-1158, Vol. 6.	
		CAIRA, M. "Molecular complexes of sulfonamides. Part 1. 1:1 complexes between sulfadimidine [4-amino-N-(4,6-dimethyl-2-pyrimidinyl) benzenesulfonamide] and 2- and 4-aminobenzoic acids" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1991, pp. 641-648, Vol. 21, No. 5.	
		CAIRA, M. "Molecular complexes of sulfonamides. Part 2. 1:1 complexes between drug molecules: sulfadimidine -acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1992, pp. 193-200, Vol. 22, No. 2.	
		CAIRA, M. "Molecular complexes of sulfonamides. 3. Structure of 5-methoxysulfadiazine (Form II) and its 1:1 complex with acetylsalicylic acid" <i>Journal of Chemical Crystallography</i> , 1994, pp. 695-701, Vol. 24, No. 10.	
		CAIRA, M. <i>et al.</i> "Order-disorder enantiotropy, monotropy, and isostructurality in a tetroxoprim-sulfametrole 1:1 molecular complex: crystallographic and thermal studies" <i>Journal of Pharmaceutical Sciences</i> , November 2003, pp. 2164-2176, Vol. 92, No. 11.	
		CAIRA, M. <i>et al.</i> "Selective formation of hydrogen bonded cocrystals between a sulfonamide and aromatic carboxylic acids in the solid state" <i>J. Chem. Soc. Perkin Trans. 2</i> , 1995, pp. 2213-2216.	
		CAIRA, M. <i>et al.</i> "Structure of a 1:1 complex between the anthelmintic drug mebendazole and propionic acid" <i>Journal of Chemical Crystallography</i> , 1998, Vol. 28, No. 1, pp. 11-15.	
		CAMERMAN, A. <i>et al.</i> "Hydrogen bonding interaction of diphenylbarbituric acid and 9-ethyladenine. Crystal structure of a 1:1 complex" <i>Can. J. Chem.</i> , 2000, pp. 1045-1051, Vol. 78.	
		CAMERMAN, A. <i>et al.</i> "Molecular structure of acetylacetone. A crystallographic determination" <i>J. Am. Chem. Soc.</i> , 1983, pp. 1584-1586, Vol. 105, No. 6.	
		CANNON, A. <i>et al.</i> "Noncovalent derivatization: green chemistry applications of crystal engineering" <i>Crystal Growth & Design</i> , 2002, pp. 255-257, Vol. 2, No. 4.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Clayton
Sheet	21	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHINNAKALI, K. <i>et al.</i> "2-aminopyrimidine and <i>p</i> -phenylene-diacetic acid (1:1) co-crystal" <i>Acta Cryst.</i> , 1999, pp. 399-401, Vol. C55.	
		CHOI, C. <i>et al.</i> "Cocrystallization of melaminium levulinate monohydrate" <i>Acta Cryst.</i> , 2004, pp. o295-o296, Vol. C60.	
		CHOW, Y. P. <i>et al.</i> "Complexation of acetaminophen with methyl xanthines" <i>Journal of Pharmaceutical Sciences</i> , 1972, pp. 1454-1458, Vol. 61.	
		CHRISTIAN, S. <i>et al.</i> "Activity coefficient effects in spectral and solubility studies of molecular complex equilibria" <i>Journal of the American Chemical Society</i> , September 20, 1972, pp. 6861-6862, Vol. 94, No. 19, Communications to the editor.	
		COLL, M. <i>et al.</i> "Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222 ₁ crystal form" <i>Journal of Biomolecular Structure & Dynamics</i> , 1990, pp. 315-330, Vol. 8, No. 2.	
		COPP, S. <i>et al.</i> "Supramolecular chemistry of [Mn(CO) ₃ (μ ₃ -OH)] ₄ : Assembly of a cubic hydrogen-bonded diamondoid network with 1,2-diamineethane" <i>J. Am. Chem. Soc.</i> , 1992, pp. 8719-8720, Vol. 114.	
		CORDI, A. <i>et al.</i> "(S)-Spiro [(1, 3-diazacyclopent-1-ene)-5, 2' -(7'-methyl-1',2',3',4'-tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial α-adrenergic agonist" <i>J. Med. Chem.</i> , 1997, pp. 2931-2935, Vol. 40.	
		CRAVEN, M. <i>et al.</i> "The 2:1 crystal complex of 5, 5-diethylbarbituric acid (barbital) and caffeine" <i>Acta Cryst.</i> , 1974, pp. 1191-1195, Vol. B30.	
		CRAVEN, M. <i>et al.</i> "The crystal structures of two polymorphs of 5,5'-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1969, pp. 1978-1993, Vol. B25.	
		CUDNEY, B. <i>et al.</i> "Screening and optimization strategies for macromolecular crystal growth" <i>Acta Cryst.</i> , 1994, pp. 414-423, Vol. D50.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/541,216	
			Filing Date	06/29/2005	
			First Named Inventor	Mark Tawa	
			Group Art Unit	1617	
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	22	of	35		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DATTA, S. <i>et al.</i> "Molecular complex formation between riboflavin and salicylate in an aqueous medium" <i>Bull. Chem. Soc. Jpn.</i> , 2003, pp. 1729-1734, Vol. 76.	
		DAVEY, R. J. <i>et al.</i> "Crystal engineering- nucleation, the key step" <i>Cryst. Eng. Comm.</i> , 2002, pp. 257-264, Vol. 4, No. 47.	
		DAVEY, R. J. <i>et al.</i> "Crystallisation in polymer films: control of morphology and kinetics of an organic dye in a polysilicone matrix" <i>J. Mater. Chem.</i> , 1997, pp. 237-241, Vol. 7, No. 2.	
		DEBERNARDIS, J. <i>et al.</i> "Conformationally defined adrenergic agents. 5. Resolution, absolute configuration, and pharmacological characterization of the enantiomers of 2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl) imidazoline: a potent agonist at α -adrenoceptors" <i>J. Med. Chem.</i> , 1987, pp. 1011-1017, Vol. 30.	
		DESIRAJU, G. <i>et al.</i> "Crystal and co-crystal" <i>Cryst. Eng. Comm.</i> , 2003, pp. 466-467, Vol. 5, No. 82.	
		DESIRAJU, G. <i>et al.</i> "Crystal engineering: outlook and prospects" <i>Current Science</i> , October 25, 2001, pp. 1038-1042, Vol. 81, No. 8.	
		DUAX, W. <i>et al.</i> "The structure of the crystalline complex estradiol. Urea (1:1)" <i>Acta Cryst.</i> , 1972, pp. 1864-1871, Vol. B28.	
		DUNITZ, J. "Crystal and co-crystal: a second opinion" <i>Cryst. Eng. Comm.</i> , 2003, pp. 506, Vol. 5, No. 91.	
		DUNITZ, J. "New light on an old story: the solid-state transformation on ammonium cyanate into urea" <i>J. Am. Chem. Soc.</i> , 1998, pp. 13274-13275, Vol. 120.	
		ENRIGHT, G. <i>et al.</i> "Thermally programmable gas storage and release in single crystals of an organic van der Waals host" <i>J. Am. Chem. Soc.</i> , 2003, pp. 9896-9897, Vol. 125.	
		EPSTEIN, R. <i>et al.</i> "The x-ray crystal structure of the molecular complex 8-bromo-9-ethyladenine-5-allyl-5-isobutylbarbituric acid" <i>Acta Cryst.</i> , 1976, pp. 2180-2188, Vol. B32.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	23	of	35		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ETTER, M. "Encoding and decoding hydrogen-bond patterns of organic compounds" <i>Acc. Chem. Res.</i> , 1990, pp. 120-126, Vol. 23.	
		ETTER, M. <i>et al.</i> "Graph-set analysis of hydrogen-bond patterns in organic crystals" <i>Acta Cryst.</i> , 1990, pp. 256-262, Vol. B46.	
		ETTER, M. <i>et al.</i> "Hydrogen bond directed cocrystallization and molecular recognition properties of acyclic imides" <i>J. Am. Chem. Soc.</i> , 1991, pp. 2586-2598, Vol. 113.	
		ETTER, M. "Hydrogen bonds as design elements in organic chemistry" <i>J. Phys. Chem.</i> , 1991, pp. 4601-4610, Vol. 95.	
		FABIAN, L. <i>et al.</i> "Volumetric measure of isostructurality" <i>Acta Cryst.</i> , 1999, pp. 1099-1108, Vol. B55.	
		FALLON III, L. "The crystal and molecular structure of 5-fluorouracil" <i>Acta Cryst.</i> , pp. 2549-2556, Vol. B29.	
		FEIBUSH, B. <i>et al.</i> "Chiral separation of heterocyclic drugs by HPLC: solute-stationary phase base-pair interactions" <i>J. Am. Chem. Soc.</i> , 1986, pp. 3310-3318, Vol. 108.	
		FIFER, E. <i>et al.</i> "Fentanyl analogues 3. 2-(1,2,3,4-tetrahydro)-naphthyl substituted 4-anilidopiperidines" <i>Eur. J. Med. Chem.-Chim. Ther.</i> , 1984, pp. 519-524, Vol. 19, No. 6.	
		RECK, G. <i>et al.</i> "Crystal structures of the carbamazepine/ammonium chloride and carbamazepine/ammonium bromide adducts and their transformation into carbamazepine dihydrate" <i>Pharmazie</i> , 1991, pp. 509-512, Vol. 46, No. 7.	X
		FOXMAN, B. M. <i>et al.</i> "Environmentally benign synthesis using crystal engineering: steric accommodation in non-covalent derivatives of hydroquinones" <i>Crystal Engineering</i> , 1998, pp. 109-118, Vol. 1, No. 1.	
		FOXMAN, B. M. <i>et al.</i> "Noncovalent derivatives of hydroquinone: BIS- (N,N-dialkyl) bicyclo[2.2.2]octane-1,4-dicarboxamide complexes" <i>Crystal Engineering</i> , 1999, pp. 55-64, Vol. 2, No. 1.	
		FUJII, S. <i>et al.</i> "Crystal and molecular structure of a 1:1 molecular complex of adenine and riboflavin" <i>Archives of Biochemistry and Biophysics</i> , 1977, pp. 363-370, Vol. 181.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	24	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GAO, X. <i>et al.</i> "Supramolecular construction of molecular ladders in the solid state" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 232-236, Vol. 43.	
		GARTLAND, G. L. <i>et al.</i> "Hydrogen bonding NH...O=C of barbiturates: the (1:1) crystal complex of urea and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 980-987, Vol. B30.	
		GHOSH, M. "Structure and conformation of the 1:1 molecular complex sulfaproxyline-caffeine" <i>Acta Cryst.</i> , 1991, pp. 577-580, Vol. C47.	
		GIUSEPPE, G. P. <i>et al.</i> "The crystal structure of a sulfamethoxazole-trimethoprim 1:1 molecular compound" <i>Il Farmaco- Ed. Sc.</i> , pp. 138-151, Vol. 35.	
		GOSWAMI, S. <i>et al.</i> "2-aminopyrimidine-fumaric acid cocrystal" <i>Acta Cryst.</i> , 1999, pp. 583-585, Vol. C55.	
		HAYNES, D. "Supramolecular synthon competition in organic sulfonates: A CSD survey" <i>Cryst. Eng. Comm.</i> , 2004, pp. 584-588, Vol. 6, No. 95.	
		GOSWAMI, S. <i>et al.</i> "1:1 Hetero-assembly of 2-amino-pyrimidine and (+)-camphoric acid" <i>Acta Cryst.</i> , 2000, pp. 477-478, Vol. C56.	
		GOSWAMI, S. <i>et al.</i> "Molecular recognition induced supramolecular array of 2-aminopyrimidine with terephthalic acid, 1,4-phenylenediacetic acid and fumaric acid in solid state via H-bonding and π -stacking interactions" <i>Supramolecular Chemistry</i> , 1999, pp. 25-33, Vol. 11.	
		GRAJA, A. <i>et al.</i> "Interplay of acceptor molecule shape, crystal structure and physical properties of a new molecular complex $C_{70} \cdot 2[(Ph_3P) AuCl]$ " <i>Chemical Physics Letters</i> , November 19, 1999, pp. 725-732. Vol. 313.	
		HAIXIN, L. <i>et al.</i> "Structure of the 1:1 complex of 6,6'-diquinolyl ether with 5,5-diethylbarbituric acid" <i>Acta Cryst.</i> , 1992, pp. 2096-2098, Vol. C48.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	25	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HENCK, J. <i>et al.</i> "Disappearing and reappearing polymorphs. The benzocaine:picric acid system" <i>J. Am. Chem. Soc.</i> , 2001, pp. 1834-1841, Vol. 123.	
		HIGUCHI, T. <i>et al.</i> "Complexation of organic substances in aqueous solution by hydroxyaromatic acids and their salts" <i>J. Pharm. Sci.</i> , 1961, pp. 905-909, Vol. 50.	
		HINO, T. <i>et al.</i> "Assessment of nicotinamide polymorphs by differential scanning calorimetry" <i>Thermochimica Acta</i> , 2001, pp. 85-92, Vol. 374.	
		HÖGBERG, T. <i>et al.</i> "Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D ₂ antagonist" <i>J. Pharm. Pharmacol.</i> , 1987, pp. 787-796, Vol. 39.	
		HSU, I. <i>et al.</i> "The 2:1 crystal complex of 2-aminopyridine and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 994-997, Vol. B30.	
		HSU, I. <i>et al.</i> "The 1:1 crystal complex of N-methyl-2-pyridone and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 998-1001, Vol. B30.	
		HSU, I. <i>et al.</i> "The crystalline complex (1:1) of salicylamide and 5-ethyl-5-isoamylbarbituric acid (amobarbital)" <i>Acta Cryst.</i> , 1974, pp. 843-846, Vol. B30.	
		HSU, I. <i>et al.</i> "The crystal structure of the 1:1 complex of acetamide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 974-979, Vol. B30.	
		HSU, I. <i>et al.</i> "The crystal structure of the triclinic 1:2 complex of hexamethylphosphoramide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 1299-1304, Vol. B30.	
		HSU, I. <i>et al.</i> "Hydrogen bonding NH...N of barbiturates: The 1:1 crystal complex of imidazole and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 988-993, Vol. B30.	
		IBRAGIMOV, B. "A simple correlation between the structures of different crystal modifications of a given host-guest complex and their crystallization temperatures" <i>Journal of Inclusion of Phenomena and Macrocyclic Chemistry</i> , 1999, pp. 345-353, Vol. 34.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/541,216	
				Filing Date	06/29/2005	
				First Named Inventor	Mark Tawa	
				Group Art Unit	1617	
Examiner Name	D. Claytor					
Attorney Docket Number	TPI5013USPCT6					
Sheet	26	of	35			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ISHIDA, T. <i>et al.</i> "Structural study of histamine H ₂ -receptor antagonists. Five 3-[2-(diamino-methyleneamino)-4-thiazolymethylthio] propionamidine and -amide derivatives" <i>Acta Cryst.</i> , 1989, pp. 505-512, Vol. B45.	
		KATAKAI, R. <i>et al.</i> "Stepwise synthesis of oligopeptides with N-carboxy-α-amino acid anhydrides. IV. Glycine NCA" <i>J. Org. Chem.</i> , 1972, pp. 327-329, Vol. 37, No. 2.	
		KAWAKAMI, Y. <i>et al.</i> "The rationale for E2020 as a potent acetylcholinesterase inhibitor" <i>Bioorganic & Medicinal Chemistry</i> , 1996, pp. 1429-1446, Vol. 4, No. 9.	
		KELDERS, H. <i>et al.</i> "Automated protein crystallization and a new crystal form of a subtilisin: eglin complex" <i>Protein Engineering</i> , 1987, pp. 301-303, Vol. 1, No. 4.	
		KHALIL, R. M. "Complexation of paracetamol with xanthine derivatives" <i>Egypt. J. Pharm. Sci.</i> , 1992, pp. 757-769, Vol. 33, No. 5-6.	
		KIM, S. "Crystal structure of the 1:1 complex of 5-fluorouracil and 9-ethylhypoxanthine" <i>Science</i> , November 24, 1967, pp. 1046-1048, Vol. 158, No. 3804.	
		KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-barbital complex" <i>Journal of Pharmaceutical Sciences</i> , May 1971, pp. 699-703, Vol. 60, No. 5.	
		KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-cyclobarbital complex" <i>Chem. Pharm. Bull.</i> , 1974, pp. 1588-1592, Vol. 22.	
		KLEIN, C. <i>et al.</i> "Molecular structure of two conformationally restrained fentanyl analogues: cis- and trans-isomers of N-[3-methyl-1-[1,2,3,4-tetrahydro) naphthyl]-4-piperidinyl]-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.	
		KOSHIMA, H. <i>et al.</i> "Photoreactivities of two kinds of bimolecular crystals formed from acridine and phenothiazine" <i>J. Chem. Soc., Perkins Trans. 2</i> , 1997, pp. 2033-2038.	
		KOSHIMA, H. <i>et al.</i> "Polymorphs of a cocrystal with achiral and chiral structures prepared by pseudoseeding: tryptamine/hydrocinnamic acid" <i>Crystal Growth & Design</i> , 2001, pp. 355-357, Vol. 1, No. 5.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/541,216	
				Filing Date	06/29/2005	
				First Named Inventor	Mark Tawa	
				Group Art Unit	1617	
				Examiner Name	D. Claytor	
Attorney Docket Number	TPI5013USPCT6					
Sheet	27	of	35			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KRISHNAMOHAN SHARMA, C. V. <i>et al.</i> "X-ray crystal structure of C ₆ H ₃ (CO ₂ H) ₃ -1,3,5•1.5(4,4'-bipy): a 'super trimesic acid' chicken-wire grid" <i>Chem. Commun.</i> , 1996, pp. 2655-2656.	
		KURODA, R. <i>et al.</i> "Generation of a co-crystal phase with coloristic properties <i>via</i> solid state grinding procedures" <i>Chem. Commun.</i> , 2002, pp. 2848-2849.	
		LEISEROWITZ, L. <i>et al.</i> "The molecular packing modes and hydrogen-bonding properties of amide: dicarboxylic acid complexes" <i>Acta Cryst.</i> , 1977, pp. 2719-2733, Vol. B33.	
		LEISEROWITZ, L. "Molecular packing modes. Carboxylic acids" <i>Acta Cryst.</i> , 1976, pp. 775-802, Vol. B32.	
		LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXXI* adducts of 2-aminopyrimidine and 3-amino-1,2,4-triazole with heterocyclic carboxylic acids" <i>Aust. J. Chem.</i> , 1998, pp. 403-408, Vol. 51.	
		MACGILLIVRAY, L. <i>et al.</i> "Supramolecular control of reactivity in the solid state using linear molecular templates" <i>J. Am. Chem. Soc.</i> , 2000, pp. 7817-7818, Vol. 122.	
		MATHIAS, J. <i>et al.</i> "Structural preferences of hydrogen-bonded networks in organic solution- the cyclic CA ₃ • M ₃ 'rosette'" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4316-4325, Vol. 116.	
		MASTROPAOLO, D. <i>et al.</i> "Hydrogen bonding interaction of diphenylhydantoin and 9-ethyladenine" <i>Molecular Pharmacology</i> , 1983, pp. 273-277, Vol. 23.	
		MARYANOFF, B. "Stereochemistry in a medium-sized ring. Highly diastereoselective N-oxidation of a substituted 3-benzazone. X-ray crystal structure of an unusual complex between an amine N-oxide and saccharin" <i>J. Org. Chem.</i> , 1990, pp. 760-764, Vol. 55.	
		MARTIN, R. <i>et al.</i> "The caffeine-potassium chlorogenate molecular complex" <i>Phytochemistry</i> , 1987, pp. 273-279, Vol. 26, No. 1.	
		ANDERSON, J. "Constitution of aurous compounds: Gold mirrors" <i>Nature</i> , October 2, 1937, pp. 583-584, Letters to the Editor.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	28	of	35		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROBBINS, A. H. <i>et al.</i> "The crystal structure of the 1:2 adduct of potassium triiodide and 5,5-diethylbarbituric acid (barbital)" <i>American Crystallographic Association- Series 2, Papers and Abstracts</i> , 1973, p. 87.	
		BEERGES, P. <i>et al.</i> "Phenothiazine tetracyanoethylene" <i>Private Communication</i> , 1994.	
		MADARASZ, J. <i>et al.</i> "Thermal, ftir and xrd study on some 1:1 molecular compounds of theophylline" <i>Journal of Thermal Analysis and Calorimetry</i> , 2002, pp. 281-290, Vol. 69.	
		CARONNA, T. <i>et al.</i> "Halogen bonding and $\pi\cdots\pi$ stacking control reactivity in the solid state" <i>J. Am. Chem. Soc.</i> , 2004, pp. 4500-4501, Vol. 126.	
		ZERKOWSKI, J. <i>et al.</i> "Steric control of secondary, solid-state architecture in 1:1 complexes of melamines and barbiturates that crystallize as crinkled tapes" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4298-4304, Vol. 116.	
		ZAITU, S. <i>et al.</i> "1:1 Molecular complex of theophylline and <i>p</i> -nitroaniline" <i>Acta Cryst.</i> , 1995, pp. 2390-2392, Vol. C51.	
		KOFLER, L. <i>et al.</i> , <u>Thermal micromethods for the study of organic compounds and their mixtures</u> , pp. 1-145, 148-351, 354-386, Innsbruck, Austria, 1980.	
		QUEHENBERGER, H. "Concerning organic molecular compounds and their polymorphism" <i>Monatshefte für Chemie</i> , 1949, pp. 595-606, Vol. 80, No. 5.	X
		WIEDENFELD, H. <i>et al.</i> "The crystal structure of the theophylline-urea complex" <i>Arch. Pharm.</i> , 1986, pp. 654-659, Vol. 319.	X
		BUNICK, G. <i>et al.</i> "The crystal and molecular structure of the complex 2,6-diamino-9-ethylpurine 5,5-diethylbarbituric acid" <i>American Crystallographic Association, Abstract Papers</i> Winter 1976, p. 30.	
		BUCZAK, G. <i>et al.</i> "Crystal structure and vibrational spectra of the 1:1 and 1:2 complexes of pyridine betaine with pentachlorophenol" <i>Journal of Molecular Structure</i> , 1997, pp. 143-151, Vol. 436-437.	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	29	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		TOMURA, M. <i>et al.</i> "One-dimensional zigzag chain structures with intermolecular C-H... π and C-H...O interactions consisted of phthalic acid and pyridine derivatives" <i>Chemistry Letters</i> , 2001, pp. 532-533.		
		ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: molecular tapes based on the network of hydrogen bonds present in the cyanuric acid-melamine complex" <i>J. Am. Chem. Soc.</i> , 1994, pp. 2382-2391, Vol. 116.		
		HARKEMA, S. <i>et al.</i> "The crystal structure of urea oxalic acid (2:1)" <i>Acta Cryst.</i> , 1972, pp. 1646-1648, Vol. B28.		
		KRANTZ, J. <i>et al.</i> "Sodium theophylline glycinate" <i>Journal of the American Pharmaceutical Association</i> , 1946, pp. 248-250.		
		DATTA, S. <i>et al.</i> "Crystal structures of drugs: advances in determination, prediction and engineering" <i>Nature</i> , January 2004, pp. 42-57, Vol. 3.		
		AAKERÖY, C. <i>et al.</i> "Charge-assisted hydrogen bonds and halogen-halogen interactions in organic salts: benzylammonium benzoates and pentafluorobenzoates" <i>Structural Chemistry</i> , 1999, pp. 229-242, Vol. 10, No. 3.		
		CHILDS, S. <i>et al.</i> "Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids" <i>J. Am. Chem. Soc.</i> , 2004, pp. 13335-13342, Vol. 126.		
		AAKERÖY, C. <i>et al.</i> "Modular supramolecular synthesis based on a dominance hierarchy of intermolecular interactions (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.		
		HELFRICH, B. <i>et al.</i> "Polymorphism as an indication of structural versatility (Abstract)" 223 rd ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.		
		WEBER, E. <i>et al.</i> "Synthesis of new Schiff bases: reaction of monofluorobenzaldehydes with 3-aminosulfolane hydrochloride (Abstract)" 216 th ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/541,216	
			Filing Date	06/29/2005	
			First Named Inventor	Mark Tawa	
			Group Art Unit	1617	
			Examiner Name	D. Claytor	
Sheet	30	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SCARBROUGH, F. <i>et al.</i> "Crystal structure of a complex between lumiflavin and 2,6-diamino-9-ethylpurine: a flavin adenine dinucleotide model exhibiting charge-transfer interactions" <i>Proc. Natl. Acad. Sci. USA</i> , November 1976, pp. 3807-3811, Vol. 73, No. 11.	
		MUNN, R. <i>et al.</i> "A Model for resonance-assisted hydrogen bonding in crystals and its graph set analysis" <i>J. Phys. Chem. A</i> , 2001, pp. 6938-6942, Vol. 105.	
		LYNCH, D. <i>et al.</i> "1:1 Molecular complexes of 4-amino-N-(4,6-dimethylpyrimidin-2-yl) benzene-sulfonamide (sulfamethazine) with indole-2-carboxylic acid and 2,4-dinitrobenzoic acid" <i>Aust. J. Chem.</i> , 2000, pp. 383-387, Vol. 53.	
		AAKEROY, C. <i>et al.</i> "Solid state, crystal engineering and hydrogen bonds" <i>Comprehensive Coordination Chemistry II</i> (ed. by McCleverty, J. <i>et al.</i>), pp. 679-688, Elsevier Ltd., Oxford, UK, 2004	
		LEVIN, B. <i>et al.</i> "The not-so-trivial synthesis and characterization of heterocyclic boronic acids (Abstract)" 38 th Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
		SMITH, G. <i>et al.</i> "Interactions of aromatic carboxylic acids with quinolin-8-ol (oxine): Synthesis and the crystal structures of the proton-transfer compounds with the nitro-substituted benzoic acids" <i>Aust. J. Chem.</i> , 2001, pp. 171-175, Vol. 54.	
		STALKER, R. <i>et al.</i> "Asymmetric synthesis of two new conformationally constrained lysine derivatives" <i>Tetrahedron</i> , 2002, pp. 4837-4849, Vol. 58.	
		VOET, D. <i>et al.</i> "Barbiturates and adenine derivatives. Molecular structure of a hydrogen-bonded complex" <i>Journal of the American Chemical Society</i> , August 9, 1972, pp. 5888-5891, Vol. 94, No. 16.	
		VISHWESHWAR, P. <i>et al.</i> "Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation" <i>Crystal Growth & Design</i> , 2003, pp. 783-790, Vol. 3, No. 5.	
		LE JEUNNE, C. <i>et al.</i> "Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks" <i>Eur. Neurol.</i> , 1999, pp. 37-43, Vol. 41.	
		AAKERÖY, C. <i>et al.</i> "Hydrogen-bonded layers of hydrogentartrate anions: two-dimensional building blocks for crystal engineering" <i>J. Mater. Chem.</i> , 1993, 1129-1135, Vol. 3, No. 11.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	31	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		HU, Z. <i>et al.</i> "Separation of 4-aminobenzoic acid by cocrystallization: Crystal structure of the complex of 4-aminobenzoic acid with (2R,3R)-tartaric acid" <i>Journal of Chemical Crystallography</i> , December 2002, pp. 525-529, Vol. 32, No. 12.		
		GUARRERA, D. <i>et al.</i> "Molecular self-assembly in the solid state. The combined use of solid state NMR and differential scanning calorimetry for the determination of phase constitution" <i>Chem. Mater.</i> , 1994, pp. 1293-1296, Vol. 6.		
		DOI, M. <i>et al.</i> "Conformational study of a potent human renin inhibitor: x-ray crystal structure of isopropyl (2R, 3S) -4-cyclohexyl-2-hydroxy-3-{N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl) propionyl] -L-histidylamino}butyrate (KRI-1314), a pentapeptide analogue with amino acid sequence corresponding to the cleavage site of angiotensinogen" <i>J. Chem. Soc. Perkin Trans. 1</i> , 1991, pp. 1153-1158.		
		CRIHFELD, A. <i>et al.</i> "Crystal engineering through halogen bonding. 2. Complexes of diacetylene-linked heterocycles with organic iodides" <i>Crystal Growth & Design</i> , 2003, pp. 313-320, Vol. 3, No. 3.		
		AAKERÖY, C. <i>et al.</i> "A versatile route to porous solids: organic-inorganic hybrid materials assembled through hydrogen bonds" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 1815-1819, Vol. 38, No. 12.		
		SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-theophylline complex.		
		SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-sulfanilamide complex.		
		WIEDENFELD, H. <i>et al.</i> "Solubilization of aminophenazone" <i>Arch. Pharm.</i> , 1982, pp. 633-641, Vol. 315.	X	
		CACCIAPUOTI, A. <i>et al.</i> "In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against <i>Aspergillus</i> and <i>Candida</i> " <i>Antimicrobial Agents and Chemotherapy</i> , August 2000, pp. 2017-2022, Vol. 44, No. 8.		
		CALLAHAN, J.C. <i>et al.</i> "Equilibrium moisture content of pharmaceutical excipients" <i>Drug Development and Industrial Pharmacy</i> , 1982, pp. 355-369, Vol. 8, No. 3.		
		DANNAOUI, E. <i>et al.</i> "Acquired itraconazole resistance in <i>Aspergillus fumigatus</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 2001, pp. 333-340, Vol. 47.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	32	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		DENNING, D. W. <i>et al.</i> "In vitro activity of Saperconazole (R66 905) compared with Amphotericin B and Itraconazole against <i>Aspergillus</i> species" <i>Eur. J. Clin. Microbial. Infect. Dis.</i> , 1990, pp. 693-697, Vol. 9.		
		DRESSMAN, J. B. <i>et al.</i> "Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms" <i>Pharmaceutical Research</i> , 1998, pp. 11-22, Vol. 15, No. 1.		
		EBERT, W. R. "Soft elastic gelatin capsules: a unique dosage form" <i>Pharmaceutical Technology</i> , October 1977, pp. 44-50, Vol. 1, No. 5.		
		GASCON, M. -P. <i>et al.</i> "In vitro forecasting of drugs which may interfere with the biotransformation of midazolam" <i>Eur. J. Clin. Pharmacol.</i> , 1991, pp. 573-578, Vol. 41.		
		HEERES, J. <i>et al.</i> "Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones" <i>J. Med. Chem.</i> , 1984, pp. 894-900, Vol. 27.		
		HONIG, P. K. <i>et al.</i> "Itraconazole affects single-dose Terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics" <i>J. Clin. Pharmacol.</i> , 1993, pp. 1201-1206, Vol. 33.		
		IMAI, T. <i>et al.</i> "Successful treatment of cerebral Aspergillosis with a high oral dose of Itraconazole after excisional surgery" <i>Internal Medicine</i> , October 1999, pp. 829-832, Vol. 38, No. 10.		
		KOVACS, J. <i>et al.</i> "New type of bridged monoamino- β -cyclodextrins" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1996, pp. 53-56, Vol. 25.		
		LAVRIJSEN, A. P. M. <i>et al.</i> "Hepatic injury associated with itraconazole" <i>The Lancet</i> , July 25, 1992, pp. 251-252, Vol. 340.		
		NEUVONEN, P. J. <i>et al.</i> "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid" <i>Clinical Pharmacology & Therapeutics</i> , 1996, pp. 54-61, Vol. 60, No. 1.		
		NOMEIR, A. A. <i>et al.</i> "Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys" <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, pp. 727-731, Vol. 44, No. 3.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
				Examiner Name	D. Claytor
Sheet	33	of	35	Attorney Docket Number	TPI5013USPCT6

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		ODDS, F. C. "Antifungal activity of saperconazole (R 66 905) <i>in vitro</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 1989, pp. 533-537, Vol. 24.		
		SAKSENA, A. K. <i>et al.</i> "Advances in the chemistry of novel broad-spectrum orally active azole antifungals: recent studies leading to the discovery of SCH 56592" in <i>Advances in the Chemistry of Novel Broad-Spectrum Orally Active Azole Antifungals</i> (Royal Soc. Chem., Cambridge), 1997, pp. 180-199.		
		SAKSENA, A. K. <i>et al.</i> "Concise asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: key intermediates towards synthesis of highly active azole antifungals SCH 51048 and SCH 56592" <i>Tetrahedron Letters</i> , 1996, pp. 5657-5660, Vol. 37, No. 32.		
		HEPPERLE, M. <i>et al.</i> "Mono <i>N</i> -arylation of piperazine(III): metal-catalyzed <i>N</i> -arylation and its application to the novel preparations of the antifungal posaconazole and its advanced intermediate" <i>Tetrahedron Letters</i> , 2002, pp. 3359-3363, Vol. 43.		
		CUTSEM, J. V. <i>et al.</i> "Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals" <i>Antimicrobial Agents and Chemotherapy</i> , December 1989, pp. 2063-2068, Vol. 33, No. 12.		
		VILLA, L. A. <i>et al.</i> "Central nervous system paracoccidioidomycosis. Report of a case successfully treated with itraconazol" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August, 2000, pp. 231-234, Vol. 42, No. 4.		
		WEST, A. R., "Solid Solutions" In: <i>Solid State Chemistry and its Applications</i> , 1988, p. 358, p. 365, Wiley, NY.		
		ARONHIME, J. <i>et al.</i> "Crystalline forms of pharmaceuticals and characterization thereof", Oral Presentation, March 8, 2005, USPTO, Alexandria, VA.		
		DESIRAJU, G. R. "Chemistry beyond the molecule" <i>Nature</i> , July 26, 2001, pp. 397-400, Vol. 412.		
		GAVEZZOTTI, A. "Are crystal structures predictable?" <i>Acc. Chem. Res.</i> , 1994, pp. 309-314, Vol. 27.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	34	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		Physician's Desk Reference, 56 th Ed., pp. 1800-1804, 2002.		
		KIM, H. <i>et al.</i> "High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum" <i>Journal of Chromatography B</i> , 2000, pp. 93-98, Vol. 738.		
		VIPPAGUNTA, S. R. <i>et al.</i> "Crystalline solids" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 3-26, Vol. 48.		
		MCCRONE, W. C. "Polymorphism", In: <i>The Physics and Chemistry of the Organic Solid State</i> , Vol. II, FOX, D. <i>et al.</i> (eds.), 1965, pp. 725-767, Interscience, New York.		
		LEGER, J.M. <i>et al.</i> "Crystal Structure of the 1:1 Sulfacetamide-Caffeine Complex" <i>Acta Cryst.</i> , 1977, pp. 1455-1459, Vol. B33.	X	
		SIMONOV, Y. <i>et al.</i> "Structure of the caffeine-copper(II) acetate additional compound", <i>Izvestiya Akademii Nauk Moldavskoi SSR, Seriya Fiziko-Tekhnicheskikh i Matematicheskikh Nauk</i> , 1972, Vol. 3, pp. 83-84, abstract only.		
		WEISSBUCH, I. <i>et al.</i> "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" <i>Acta Cryst.</i> , 1995, B51:115-148.		
		FAUGHT, E. <i>et al.</i> "Topiramate Dose-Ranging Trial in Refractory Partial Epilepsy", <i>Amer. Epilepsy Soc. Proc.</i> , (1995), pg. 33, Vol. 36, Supp. 4.		
		PRIVITERA, M. <i>et al.</i> "Dose-Ranging Trial with Higher Doses of Topiramate in Patients with Resistant Partial Seizures", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.		
		SACHDEO, S. K. <i>et al.</i> "Topiramate: Double-Blind Trial as Monotherapy", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.		
		Press Release. "Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability". http://www.orthomcneil.com/news/article020402.html (February 4, 2002), N.J.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/541,216
				Filing Date	06/29/2005
				First Named Inventor	Mark Tawa
				Group Art Unit	1617
Examiner Name	D. Claytor				
Attorney Docket Number	TPI5013USPCT6				
Sheet	35	of	35		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		ROSENFELD, W. E. "Topiramate: A Review of Preclinical, Pharmacokinetic, and Clinical Data", <i>Clinical Therapeutics</i> , 1997, pp. 1294-1308, Vol. 19, No. 6.		
		Physician's Desk Reference, 56 th Edition, 2002, pp. 2590-2595.		
		BRADER, M.L. <i>et al. Nature Biotechnol.</i> , 2002, 20 :800-804.		
		EL-NAHHAS, S.A. <i>Pharmazie</i> , 1996, 51(12):960-963.		
		FLEISCHMAN, S.G. <i>et al. Crystal Growth & Design.</i> , 2003, 3(6): 909-919.		
		OSWALD, I.D.H. <i>et al. Acta Cryst.</i> , 2002, B58:1057-1066.		
		REYNOLDS, J.E.F. (ed). Martindale, The Extra Pharmacopoeia, 1993, The Pharmaceutical Press, London, England, 13 th Edition, pp. 1431 (e.g., Acetaminophen, Aspirin, and Caffeine Tablets), 1465 (e.g., Aspirin plus C), 1521 (Codafen Continus), 1610 (Gaboril Complex).		
		WALSH, R.D. Bailey <i>et al. Chem. Commun.</i> , 2003:186-187.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.